RE:RE:RE:RE:$tltff The FDA wants an option that has rates better thenYou read the stats wrong, stocksnbonds... The response is actually proving to be pretty durable with our PDT.
The 19% you see is the small minority of patients who have reached 360... In time, that percentage will balloon.
But I'm actually glad the results are so hard for the uninitated to read... First, it allows the company to seem like they're underpromising while actually overdelivering, and...
It allows me to get some more cash together while the price is still so low, lol. stocksnbonds458 wrote: Perhaps a silly question, but say for example TLT's product was on the market and a patient knew they had a 70% chance be CR at 90 days, and only a 19% chance of being CR at 360 days. Knowing this could be a potential oucome, would not all patients request to continue to receive this treatment on a continuous basis , such that the likelihood of a return of cancer is unlikely? In other words, in the real would not treatments of TLD1433 provide 70% of all patients a CR for the rest of their lives?